Public Employees Retirement System of Ohio Purchases 3,003 Shares of United Therapeutics Corporation $UTHR

Public Employees Retirement System of Ohio grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 13.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,010 shares of the biotechnology company’s stock after purchasing an additional 3,003 shares during the period. Public Employees Retirement System of Ohio’s holdings in United Therapeutics were worth $14,830,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in UTHR. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC increased its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $31,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, HC Wainwright upped their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $648.33.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,921,276.08. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 493,833 shares of company stock worth $275,841,047. 8.60% of the stock is owned by insiders.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $528.47 on Monday. The stock has a market capitalization of $22.43 billion, a PE ratio of 19.51, a P/E/G ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The business’s fifty day moving average price is $547.88 and its 200-day moving average price is $531.69.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $6.63 EPS. As a group, equities analysts expect that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.